Published in Endocrinology on October 20, 2005
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res (2010) 1.65
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta (2010) 1.32
Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res (2007) 1.31
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell (2014) 1.19
Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. Proc Natl Acad Sci U S A (2006) 1.16
Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res (2010) 1.07
The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol (2009) 0.97
Inhibition of oxygen-induced hypoxia-inducible factor-1alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology (2009) 0.86
How to improve postgenomic knowledge discovery using imputation. EURASIP J Bioinform Syst Biol (2009) 0.78
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer. Br J Cancer (2014) 0.78
Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer (2016) 0.77
Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. Horm Cancer (2013) 0.76
Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells. Horm Cancer (2014) 0.75
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst (2002) 4.09
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol (2004) 2.39
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res (2006) 2.38
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol (2003) 2.20
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res (2003) 2.01
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol (2002) 1.99
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res (2004) 1.89
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer (2003) 1.87
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A (2008) 1.76
Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res (2011) 1.74
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (2010) 1.64
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res (2008) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Lobular neoplasia on core-needle biopsy--clinical significance. Cancer (2004) 1.57
Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol (2007) 1.56
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol (2012) 1.53
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol (2011) 1.43
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res (2006) 1.43
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res (2004) 1.42
Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J (2002) 1.42
The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression. J Biol Chem (2002) 1.40
Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc Natl Acad Sci U S A (2006) 1.32
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol (2004) 1.32
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol (2008) 1.32
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat (2010) 1.31
Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol (2003) 1.31
Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A (2011) 1.30
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther (2012) 1.26
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia (2012) 1.25
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res (2012) 1.23
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.23
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res (2005) 1.23
Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res (2006) 1.21
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg (2005) 1.20
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer (2003) 1.18
MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer (2010) 1.18
GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway. Mol Cell Biol (2006) 1.17
Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol (2006) 1.17
Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res (2005) 1.14
microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.14
Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res (2012) 1.10
Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat (2003) 1.08
New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem (2002) 1.08
Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res (2010) 1.07
Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab (2008) 1.07
Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis (2007) 1.06
Steroid receptor coactivator 2 is required for female fertility and mammary morphogenesis: insights from the mouse, relevance to the human. Nucl Recept Signal (2007) 1.06
Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res (2010) 1.05
Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol (2008) 1.02
miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One (2012) 1.02